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Gut microbiota plays a key role in host physiology and metabolism. Indeed, the 
relevance of a well-balanced gut microbiota composition to an individual´s health status 
is essential for the person's well-being. Currently, investigations are focused on 
analyzing the effects of pre- and probiotics as new therapeutic tools to counteract the 
disruption of intestinal bacterial balance occurring in several diseases. Polyphenols 
exert a wide range of beneficial health effects. However, although specific attention has 
been paid in recent years to the function of this “biological entity” in the metabolism of 
polyphenols, less is known about the modulatory capacity of these bioactive compounds 
on gut microbiota composition. This review provides an overview of the latest 
investigations carried out with pure polyphenols, extracts rich in polyphenols and 
polyphenol-rich dietary sources (such as cocoa, tea, wine, soy products and fruits), and 
critically discusses the consequences to gut microbiota composition which are 
produced. 




Polyphenols are members of a very large family of plant-derived compounds that show 
an extensive variety of chemical structures. They are classified as flavonoids and non-
flavonoids. Among the flavonoids, various groups can be distinguished: flavonols, 
flavan-3-ols (monomeric and polymeric structures), flavones, isoflavones, flavanones 
and anthocyanidins. Among non-flavonoids we find stilbenes, hydrolysable tannins and 
phenolic acids.1 The polyphenolic profile of vegetables and fruits very much depends on 
the type of plants, on the conditions under which these plants are grown, on harvest 
conditions and how these products are stored. 
Polyphenols can have beneficial effects on human health, and thus their study has 
become an increasingly important area of human nutrition research. A great number of 
epidemiological studies have shown that the consumption of diets rich in fruits and 
vegetables is associated with a reduction in the risk of suffering chronic diseases, such 
as cardiovascular diseases, specific cancers or neurodegenerative diseases. In order to 
confirm these observations, numerous intervention trials have been conducted in recent 
years. The beneficial effects of phenolic compounds on different health issues have 
been reviewed elsewhere.2  
Taking into account current scientific evidences about the beneficial effects induced by 
polyphenol intake, despite the low bioavailability of these molecules, further studies are 
required to analyze whether polyphenol metabolites contribute to the effects of their 
parent compounds. However, the investigations reported concerning this topic are 
scarce. In this context, the role of gut microbiota, which determines to some extent the 
polyphenol metabolite profile, is an important issue to be addressed.3,4 The action of gut 
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microbes on polyphenols leading to the production of metabolites with diverse 
physiological relevance has been also analyzed in the recent years.5
This review aims to highlight the impact of phenolic compounds, either as pure 
compounds or as food constituents, on gut microbiota composition and intends to offer 
an update of the recent in vitro and in vivo evidence which demonstrates the interaction 
existing between gut microbes and polyphenols with health impact. 
Gut microbiota and health 
The intestine is the largest reservoir of human flora, which achieves concentrations of 
up to 1011 or 1012 cells/g and consists of a complex microbial community residing the 
gut called microbiota. The human body has about 100 trillion microorganisms in the 
intestine, which is ten times higher than the total number of human cells in the body. 
Only a minority of the species that inhabit the human colon has been identified so far, 
but modern molecular methods such as broad-range sequencing of 16S ribosomal RNA 
from amplified bacterial nucleic acids extracted from faeces or biopsies, are being used 
nowadays to identify and classify intestinal bacteria6. 
Bacteria make up most of the flora in the colon, where around 300-500 different species 
live.6 The most common bacteria are Bacteroides which constitute around 30% of all 
bacteria in the gut, followed by Clostridium, Prevotella, Eubacterium, Ruminococcus, 
Fusobacterium, Peptococcus, and Bifidobacterium. Escherichia and Lactobacillus are 
also present, but at lesser extent.7 It seems that 99% of the bacteria come from about 30 
or 40 species.7
It has been reported that diet has a major influence on gut microbiota and is able to 
modify their impact on health, with either beneficial or deleterious consequences.8 Thus, 
levels of Prevotella are enriched in children who have had a high-fiber diet9, as well as 
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in children and adults whose diet is dominated by plant-derived polysaccharide foods, 
such as maize and cassava. By contrast, the microbiota of people with a long-term diet 
rich in animal protein and saturated fat has more Bacteroides.10 These changes can be 
explained by fiber content of the diet. The increase in colonic fermentation results in a 
decrease in the pH, from 6.5 to 5.5, due to the high concentrations of short-chain fatty 
acids. This decrease in the pH has a profound selective effect upon the colonic 
microbial community in fermentor simulations supplied with soluble polysaccharides, 
with a tendency to suppress Bacteroides spp. and to promote butyrate-producing gram-
positive bacteria.11 However, long-term periods (8-9 weeks) of dietary patterns are 
needed to induce changes in the microbiota of individuals.12
During the metabolism of foods and xenobiotics, the host and its gut microbiota 
coproduce a large amount of small molecules, many of which play critical roles in 
shuttling information between host cells and the host’s microbial symbionts (cross-talk). 
In this context, alterations in the microbiome, dysbiosis, modulate the metabolic 
phenotype of the host, and greatly influence host biochemistry and susceptibility to 
diseases.13 Indeed, it has been proposed that gut microbiota are involved in appetite 
control, energy balance, obesity, diabetes, immune function, allergies, behavioral 
perturbations, cardiovascular disease and cancers, such as stomach cancer.8
Polyphenols and gut microbiota interactions 
The percentage of polyphenol absorption is very low14 and as much as 90% of these 
compounds persist into the colon. There, they are metabolized via esterase, glucosidase, 
demethylation, dehydroxylation and decarboxylation activities of bacteria,15 resulting in 
smaller metabolites such as phenolic acids and short chain-fatty acids, some of which 
can be absorbed across the intestinal mucosa. Interestingly, the microbial bioconversion 
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capacity of each individual influences the final metabolites produced and impacts on 
their bioavailability. Indeed, since all individuals have their own unique signature of 
intestinal microbiota, which can make an analogy with a fingerprint, human intestinal 
microbiota composition can modulate the polyphenol impact on host health.15,16
On the other hand, polyphenols and their metabolites can affect the intestinal ecology 
modulating microbiota.15 In this sense, several phenolic compounds have been 
identified as potential antimicrobial agents with bacteriostatic or bactericidal actions. 
Furthermore, they could also act as inhibitors of infection-causing bacteria within cells 
of the intestinal and urinary tracts, suggesting that some phenolic compounds have 
potential to be applied as antimicrobial agents against human infections.15
Despite these positive effects, it is important not to forget that excessive amounts of 
polyphenols may also inhibit the growth of colonic beneficial microbiota, which is 
responsible for bioconversion of polyphenols, and thus indirectly interfere with their 
own bioavailability. Consequently, dietary supplementation may exert a non-desirable 
effect on human health instead of supporting it.16
Influence of phenolic compounds in gut microbiota composition 
The majority of studies encompassing the influence of phenolic compounds on gut 
microbes have been focused on their anti-microbial activity. However, the concept of 
polyphenols as potential prebiotic candidates could be considered as a newly emerging 
concept. 
Interestingly, a number of in vitro and in vivo (in animals and humans) studies showing 
the influence of dietary polyphenols on gut-inhabiting bacteria have been published in 




Flavanones and flavonols 
The impact of some flavanones (naringenin, naringin, hesperetin, hesperidin) and 
flavonols (quercetin and rutin), on specific intestinal microbial representatives was 
screened in vitro by Duda-Chodak.16 For this purpose, pure cultures of 6 bacteria 
species (Bacteroides galacturonicus, Lactobacillus sp., Enterococcus caccae, 
Bifidobacterium catenulatum, Ruminococcus gauvreauii and Escherichia coli) were 
inoculated with pure polyphenols at final concentrations of 4, 20 and 50 µg/mL in the 
case of quercetin and at 20, 100 and 250 µg/mL for the rest of the compounds. 
Naringenin and quercetin exerted a complete and dose-dependent inhibitory effect on 
the growth of all analyzed bacterial species, whereas this effect was weaker for 
hesperetin. A higher inhibitory effect of the aglycones, compared to that of the 
glycosides (naringin, rutin and hesperidin), was demonstrated.16 The fact that flavanone 
glycosides were unable to exert any antimicrobial activity was explained by the 
dependency of the potential of these compounds on the sugar presence/absence in the 
moiety.  
In another in vitro study conducted by Kawabata et al.17 Bifidobacterium adolescentis, 
one of the probiotic species usually identified in the intestine of both children and 
adults, was co-cultured with different flavonols (galangin, kaempferol, quercetin, 
myricetin and fisetin) and the growth rate measured.17 All the flavonoids studied, except 
galangin, showed little or no anti-bacterial effect. In addition, when these conditioned 
media were exposed to a nitric oxide (NO) production inhibition assay, the co-culture of 
B. adolescentis with galangin (54%), quercetin (50%) and fisetin (76%) decreased NO 
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synthesis, suggesting an improvement in flavonol anti-inflammatory capacity by B. 
adolescentis.17  
Backing up these findings, another study tested pure polyphenols at concentrations 
ranging from 62.5-1000 µg/mL and their influence on the viability of four bacterial 
strains (Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and 
Lactobacillus rhamnousus) was assessed.18 All polyphenols, except rutin, induced a 
decrease in bacterial growth, but specifically quercetin (flavonol) and naringenin 
(flavanone) presented the highest anti-bacterial activities with the lowest minimum 
inhibitory concentration (MIC) values. Although Gram-negatives tested had similar 
sensitiveness to polyphenols, within Gram-positive populations, S. aureus was the most 
sensitive, while L. rhamnosus required a MIC of at least 125 µg/mL.18
Flavanols 
In a study that investigated the effect of flavanol monomers, namely (-)-epicatechin and 
(+)-catechin, on the growth of specific bacterial populations, a marked overgrowth of 
beneficial bacterial groups was noted when microbiota was exposed to 150 mg/L or 
1000 mg/L of (+)-catechin.19 Both concentrations promoted the growth of Eubacterium 
rectale- Clostridium coccoides, and the lowest concentration was able to induce that of 
Lactobacillus spp. and Bifidobacterium spp. Moreover, (+)-catechin inoculation at 150 
mg/L induced the growth of Escherichia coli and the 1000 mg/L concentration 
decreased that of Clostridium histolyticum. A significant increase in the growth of 
Eubacterium rectale- Clostridium coccoides was also reported with the inoculation of (-
)-epicatechin at 150 mg/L concentration.19 The inhibitory potential of (+)- catechin at 
concentrations raging 20 to 250 µg/mL, on specific intestinal microbial representatives 
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was reported to be powerless as it was only able to slightly slow down the growth of B. 
catenulatum (MIC >250 µg/mL), but promoted the growth of E. caccae.16
Polyphenon G powder, a purified preparation of tea-derived catechins, was also 
reported to induce a significant increase in lactobacilli and a marked decrease in 
Enterobacteriaceae in broiler chickens.20  
The implication of the principal tea phenolic aglycones, epicatechin, catechin, 3-O-
methylgallic acid, gallic acid and caffeic acid, on pathogenic, commensal and probiotic 
intestinal bacteria was investigated in an in vitro study by Lee et al.21 In agreement with 
the effects previously mentioned, these compounds suppressed the growth of pathogens 
like Clostridium perfrigens, Clostridium difficile, and Bacteroides spp., with commensal 
anaerobes (Clostridium spp. and Bifidobacterium spp.) and probiotics (such as 
Lactobacillus spp.) being affected in a much lower extent. Caffeic acid was evidenced 
to be the strongest inhibitor, especially for Eschericia coli, Salmonella, Pseudomonas, 
Clostridium and Bacteroides.21
Isoflavones 
Gut microbiota composition has been reported to play a key role in the degradation of 
isoflavones and studies are being conducted to unveil the bacterial strains responsible. 
Nonetheless, studies analyzing the effect of isoflavone supplementation on gut 
microbiota composition are scarce. Clavel et al.22 found that isoflavone supplementation 
(100 mg/d) to postmenopausal women during two months, produced a bifidogenic 
effect with increases in Bifidobacterium species.22 In this trial, isoflavones were 
reported to alter dominant bacterial communities with increases in Clostridium 
coccoides- Eubacterium rectale (Erec) cluster, Faecalibacterium prasnutzii subgroup 
and Lactobacillus-Enterococcus group. However, unlike Bifidobacterium species, the 
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concentrations of the Erec-cluster were suggested to be linked to the obtention of equol, 
an intestinal metabolite from daidzein.
Condensed tannins (proanthocyanidins) 
Condensed tannins, which are also called proanthocyanidins, are present in a broad 
number of higher plant species. Regarding the effect of these compounds on gut 
microbiota, the effects of diet supplementation with low-tannin (0.7%) and high-tannin 
(2.0%) diets were assessed in rats by Smith et al.23 Shifts in bacterial populations of 
faeces were analyzed by DNA fingerprinting and bacterial cultivation and enumeration. 
The authors concluded that the most predominant groups in condensed-tannin 
supplemented animals were those belonging to Enterobacteriaceae, Bacteroides- 
Prevotella- Porphyromonas and the Bacteroides fragilis group.23  
Nonflavonoids 
Stilbenes 
The antimicrobial effects of resveratrol (3,5,4´-trihydroxy-trans-stilbene) against 
several pathogenic agents has been reported in vitro. When this compound was 
administered to a DSS-induced colitis rat model, a significant increase in lactobacilli 
and bifidobacteria, as well as decrease of enterobacteria, was observed after 20 days.24 
Hydrolysable tannins (ellagitannins)  
Ellagitannins, a type of hydrolysable tannin, are hydrolized in vivo and releases ellagic 
acid, whose metabolism by gut microbiota results in urolithin production25. The effect 
of these tannins on the growth of intestinal bacteria is limited and generally their 
antimicrobial potential has been evaluated in vitro. In relation to this, Bialonska et al. 26 
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analyzed the effect of a commercial extract of pomegranate at 0.01%, as well as the 
effect of its main constituents (0.05%) on the growth of several intestinal bacteria by 
liquid culturing. A strong inhibition capacity was observed with punicalagins and 
ellagic acid, especially against Clostridium species, while a repression in pathogenic 
Staphylococcus aureus growth was only obtained with the pomegranate extract and 
punicalagins. Interestingly, the growth of probiotic lactobacilli and bifidobacteria was 
less affected.26 Moreover, the same group aimed to prove whether this trend was 
maintained using a fermentation batch-culture system inoculated with faecal samples 
from healthy individuals, which better simulate conditions from colonic region. In this 
experiment, pomegranate extract was able to produce an increment on total bacterial 
number, enhancing the growth of Bifidobacterium spp., Lactobacillus and Enterococcus 
groups, while no effect was observed for C. histolyticum group.27 In a different study, 
the growth of Escherichia coli (half maximal inhibitory concentration, IC50=9.2 µM) 
and Pseudomonas aeruginosa (IC50= 3.2 µM) was suppressed by punicalagins and 
gallagic acid, while ellagic acid and punicalins did not exhibit any antimicrobial 
activity. The authors could not correlate these results with the structural differences of 
the compounds.28
Polyphenol-rich dietary sources and gut microbiota composition 
Cocoa  
Cocoa, a product derived from Theobroma cacao L. (Sterculiaceae), is rich in flavan-3-
ols, in the form of monomeric (-)-epicatechin and (+)-catechin, as well as type- B 
proanthocyanidins. The fact that cocoa polyphenols ingestion could affect diseases, 
such as hypertension, oxidative stress, cancer, atherosclerosis, diabetes, and diverse 
central nervous system disorders, and the fact that these disorders have also been linked 
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to gut microbiota, has opened a research gate to investigating the effect of cocoa or 
chocolate intake on gut microbiota. In this regard, the faecal microbiota composition 
was analyzed after a high and continuous (10% w/w) cocoa intake in female Wistar 
rats.29 The authors reported significantly lower levels of Bacteroides, Staphylococcus 
and Clostridium genera at the end of the intervention. Moreover, reductions in 
Clostridium species were found to correlate with weight loss and body mass index 
(BMI) z-score.29
A human intervention study conducted with low-cocoa flavanol (LCF, 29 mg) and high-
cocoa flavanol (HCF, 494 mg) drinks over 4 weeks, described a significant increase in 
Lactobacillus spp. (P<0.001) and Bifidobacterium spp. (P<0.001) when the HCF was 
compared to the control LCF beverage.30 This condition was suggested to be partly 
responsible for the reductions observed in C-reactive protein (mg/mL) (CRP) plasma 
levels (-30%). On the other hand, a significant decrease in C. histolyticum group (P< 
0.001) was stated, a group that includes C. perfringens pathogen, an agent contributing 
to a wide range of human diseases.30 
Tea 
Flavonoids in tea (from the plant Camellia sinensis) occur in large quantities, the major 
classes being catechins, including epicatechin, epigallocatechin, epicatechin-3-gallate, 
and epigallocatechin-3-gallate. Moreover, flavanols, such as quercetin, kaempferol, 
myricetin and their glycosides are also found. The linkage between tea consumption and 
gut microbiota as a possible explanation for its contribution to well-being is under 
investigation. Ahn et al.,31 reported that green tea extracts (GTE) repressed the growth 
of Clostridium bifermentans, C. difficile, C.innocuum, C. paraputrificum, C. perfringens 
and C. ramosum, while encouraging the growth of Bifidobacterium spp. in vitro.31 In an 
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in vitro study conducted by Kemperman et al.,32 the antimicrobial effect of a black tea 
extract was analyzed by traditional culturing and qPCR, and its impact on microbial 
community was also assessed by PCR-DGGE and 16S rDNA measurements.32 Several 
animal studies conducted in pigs33 and in calves34 concluded that tea polyphenols 
produced an enhancement in animals’ intestinal microbiota. Thus, pigs that received 
0.2% of tea polyphenols for 2 weeks showed a significant decrease in total bacteria and 
bacteroidaceae and a tendency to decrease in C. perfringens. By contrast, a significant 
increase in Lactobacilli was found33. Similarly, two types of GTE were tested in vitro 
(GTE-1 and GTE-2, polyphenol contents >60% and >80%, respectively) and MICs 
were determined for diverse pathogenic bacteria. As a result of these in vitro analyses, a 
stronger inhibitory capacity of GTE-2 was concluded, assuming that the higher amounts 
of (-)-epigallocatechin gallate, (-)-gallocatechin gallate and (-)-epicatechin gallate might 
be responsible for the observed reduction in bacterial growth. Furthermore, within the 
large variability of MICs detected for the tested species, the total counts of 
Bifidobacterium spp. and Lactobacillus spp. were significantly higher in the test group. 
In the same study, the growth rate reduction of C. perfringens was faster in calves 
supplemented with GTE, supporting the potential of GTE to prevent the growth of 
pathogenic bacteria and to improve microflora balance.34  
In humans, a product containing 70% of tea polyphenols (Sunphenon®, which included 
(+)-catechin, (-)-epicatechin, (+)-gallocatechin, (-)-epigallocatechin, (-)-epicatechin 
gallate, (-)-gallocatechin gallate, and (-)-epigallocatechin gallate) was administered 
(0.4g/volunteer) 3 times per day, for 4 weeks, which was equivalent to 10 cups of 
concentrated green tea. Results indicated that C. perfringens and other Clostridium spp. 
were significantly reduced during the tea polyphenol intake periods, whereas 
percentages of Bifidobacterium spp. in total faecal counts markedly increased.35 More 
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recently, bifidobacteria showed a trend to increase in 10 volunteers who drank green tea 
for 10 days.36 In a different study, the effect of 4% green tea powder (GT) supplement 
with or without the addition of Lactobacillus plantarun DSM 15313 (Lp), was 
evaluated on microbiota of small intestine and caecum of high-fat fed mice. This study 
showed a synergestic effect with significant increases in Lactobacillus group and 
bacterial diversity, in both, small intestine and caecum, after 22 weeks.37  
Wine 
Benefits coming from the moderate consumption of red wine (RW) have been mostly 
attributed to its phenolic compounds, consisting of a complex mixture of flavonoids, 
such as flavan-3-ols and anthocyanins, but also, of nonflavonoids, such as resveratrol, 
cinnamates and gallic acid. Similarly to the polyphenols derived from other food 
products, wine polyphenols have also been stated to display a selective modulation of 
gut microbiota32. Thus, Dolara et al.38 reported changes in the main bacterial strains of 
wine polyphenol-treated F344 rats (50 mg/kg for 15 weeks) compared to the control-fed 
rats. The wine polyphenolic extract contained 4.4% anthocyanins, 0.8% flavonols, 2.0% 
phenolic acids, 1.4% catechin, 1.0% epicatechin and 28% proanthocyanidin. 
Bacteroides, Lactobacillus and Bifidobacterium spp. were more predominant in faeces 
of polyphenol-treated rats, whereas Bacteroides, Clostridium and Propionibacterium 
spp. prevailed in control-fed rats’ faeces. The authors underlined the potentiality of wine 
polyphenols to simulate the favourable effects of fibres and prebiotics on the colonic 
bacterial content.38 An in vitro batch culture fermentation model carried out with human 
faecal microbiota aimed to observe the bacteria- polyphenol interactions implicated in 
the colonic metabolism of RW polyphenols.39 In this study, the slight inhibition 
observed in Clostridium histolyticum were in concordance with the conclusions drawn 
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with monomeric flavan-3-ols and cocoa flavan-3-ols in previously mentioned batch 
culture models.19,30 Nevertheless, the lack of positive effects found on the growth of 
Lactobacillus/Enterococcus spp. in this experiment,39 was ascribed to the lower 
concentrations of flavan-3-ol compounds provided (20.94 mg/L) compared to the 219 
mg/L used by Tzounis et al.19,30 In an intervention study, Queipo-Ortuño et al.40 
investigated the changes produced in the faecal microbiota of ten healthy human 
volunteers after the consecutive intake of RW, dealcoholized red wine (DRW), and gin. 
After a washout period of two weeks, the small number of participants enrolled to the 
study was crossed from one treatment to the other, which might help the authors having 
a greater statistical power. However, the fact that there were three treatments with the 
absence of washout periods between them was a limitation that required discussion. 
Based on data from the monitorization of urine resveratrol metabolites after each 
treatment, the authors were able to conclude that there was not any carryover from 
treatment to treatment, thus, this issue was discarded as a confounding factor.40 
Regarding gut microbiota, differences were observed depending on the type of beverage 
consumed. Briefly, four mayor bacteria phyla (Proteobacteria, Fusobacteria, 
Firmicutes and Bacteroidetes) were markedly increased after RW intake, and relevant 
increases in Bifidobacterium and Prevotella species were detected. In contrast, no 
changes were found in Actinobacteria phyla and marked decreases were identified in 
the Clostridium genera and Clostridium histolyticum group with RW. Nevertheless, 
these effects were less pronounced or even disappeared with DRW. Interestingly, the 
induction of gut microbiota remodelling due to the intake of small amounts of ethanol 
with polyphenols, was linked to reductions in blood pressure, triglycerides, total 
cholesterol and CRP.40  Table 1 summarizes the main results from studies analyzing 
polyphenol-rich beverages and gut microbiota composition. 
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Soy products  
Soy products, coming from soybeans (members of Leguminosae), are rich in 
phytoestrogens, principally in the form of isoflavones. At this stage, a study that 
evaluated the impact of diverse soymilk formula consumption on the intestinal 
ecosystem of human overweight and obese men found a better Firmicutes to 
Bacteroidetes ratio in the soymilk-fed groups.41 Soymilk intake in newborns was found 
to slightly enlarge the number of Bifidobacterium species in the infants.42 Nevertheless, 
neither analyzed the isoflavone content of the soymilk or soy formula milk used; 
therefore, the slight modifications observed could not be attributed to specific 
components of the milk. The use of the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME) to prove the influence of a soygerm powder in the fermentative 
capacity of bacteria from inoculated faecal samples has been focus of interest.43 
Moreover, in vivo studies with probiotic soy products have been also performed and 
differences on fecal microbiota have been reported. Bedani et al.,44 analyzed bacterial 
genus composition in rats faeces that were administered the Enterococcus faecium CRL 
183 probiotic microorganism with a soy product, either as a pure cell suspension or as a 
fermented product. Data were compared to microbial changes observed in rats treated 
with the unfermented soy product. In this case, no reductions in pathogenic genus such 
as, Clostridium spp., Bacteroides spp. or enterobacteria were concluded for the animals 
treated with the fermented soy products and only an enhancement in the growth of 
Lactobacillus spp. was obtained for the animals administered the E. faecium 
suspension.44 Cavallini et al.,45 in contrast, performed another experiment, in which a 
probiotic soy product was administered to white rabbits and posterior analyses of 
microbiota were performed in vitro. In this case, the difference in bacterial populations 
obtained between fermented and unfermented products were more significant regarding 
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Lactobacillus spp. and Bifidobacterium spp. populations, which might be attributed to 
the addition of probiotic bacteria (E. faecium CRL 183 and L. helveticus 416). In fact, it 
could be observed that unfermented soy products are able to reduce Clostridium species, 
while fermented soy products, in general, produce an enhancement in the growth of 
probiotic bacteria.45
Fruits 
A great deal of evidence suggests that fruits, vegetables and products coming from 
them, are able to significantly boost the growth of colonic friendly bacteria, as for 
example Bifidobacterium and Lactobacillus. Table 2 presents data about the influence 
of some selected fruits and soy products on gut microbiota composition. 
Pomegranate 
Scientific research has evidenced the high antioxidant capacity of pomegranate (Punica 
granatum L.) products, which has been attributed to their high content in antioxidants 
and anti-inflammatory bioactive compounds (ellagitannins and anthocyanins mainly) 
concentrated in peel, membranes and piths. In this context, experiments using batch-
culture fermentation systems have aimed to examine the potential of pomegranate peel 
extract (PPE) and punicalagins in the growth of intestinal bacterial strains. In these 
studies, PPE (0.01%) inhibited the growth of C. perfringens, C. ramosum, 
Staphyloccoccus aureus and C. clostridioforme, but significantly enhanced the growth 
of B. breve and B. infantis by 275% and 241%, respectively.26 In a similar study, 
Bialonska et al.27 stated a significant increase of total bacteria and beneficial bacteria 
Bifidobacterium spp. and Lactobacillus- Enterococcus group in media supplemented 
with PPE, which was accompanied by a marked increase in the production of short 
chain fatty acids. In contrast, no significant effect was observed in gut bacteria grown in 
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media supplemented with punicalagins (0.2% w/v).27 Larrosa et al.46 reported for the 
first time the prebiotic effect of PPE using a dextran sodium sulphate- induced colitis rat 
model. The intake of 250 mg PPE/kg/day (equivalent to 2.5 g PPE in a 70 kg-person) 
for 3 weeks increased Bifidobacterium, Lactobacillus and Clostridium counts 
preventing the colonization and invasion of tissues by enterobacteria including E. coli. 
In addition, the same results were obtained when the rats were fed synthetic urolithin A 
(2.2 mg/kg/day; equivalent to 154 mg in a 70 kg person), which demonstrated that the 
main gut microbiota- derived metabolite from pomegranate ellagitannins, urolithin A, 
also showed prebiotic effect.46 Neyrinck et al.47 emphasized the enhancement of the 
caecal pool of bifidobacteria in mice fed a high-fat diet supplemented with the PPE (rich 
in polyphenols, 30%). In addition, a down-regulation of the expression of inflammatory 
markers (IL-1β, IL-6, COX-2) in colon and visceral adipose tissue was demonstrated for 
the latter group. Therefore, a direct relationship between PPE consumption and health 
improvement through gut microbiota modulation was hypothesized by the authors.47
Apples 
Apple contains a high amount of pectin, a polysaccharide fiber that has been described 
to influence intestinal microbiota, but is also rich in phenolic compounds with high 
antioxidant capacity. Licht et al.48 argued that changes in the microbiota of apple-fed 
rats should be ascribed to pectin.48 Rats that received an extraction juice from apples 
(total polyphenols, 829 mg/L) for 4 weeks, instead of drinking water, showed 
significantly more Lactobacillus and Bifidobacterium in fresh faeces.49 The same 
research group also observed an increase in Bacteroidaceae species in Wistar rats’ 
offered juice colloids isolated from apple pomace extraction juices, which presented 
higher contents of dietary fiber and polyphenols.50 Moreover, as previously reported, in 
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a study where apple pectin (5 g/100 g) and polyphenol-rich apple concentrate (10 g/100 
g) was given to rats, even if microbiota analyses were not conducted, a more effective 
biological effect was demonstrated when both components were administered in 
combination, implying the important role of the phenolic compounds.51  
Grapes 
Grape fruits are rich in polyphenols, mainly, anthocyanins, flavonols, favan-3-ols, 
hydroxybenzoates and phenolic acids. An in vitro study was conducted in order to 
analyze the potential of two grape seed flavan-3-ol fractions in the growth and 
metabolism of Bifidobacterium spp., Lactobacillus/Enterococcus spp., Clostridium 
histolyticum group, Bacteroides spp. and members of the domain Bacteria.52 The 
analyzed grape seed extracts (GSE) differed in their composition of monomers and 
oligomers. Monomeric-rich fraction of GSE (GSE-M) contained 70% monomers and 
28% procyanidins, whereas oligomeric-rich fraction of GSE (GSE-O) was composed of 
21% monomers and 78% procyanidins. In spite of these composition differences, both 
extracts produced comparable effects on microbiota composition. For instance, a 
selective inhibitory action on Clostridium histolyticum was described for both fractions 
within 5-10 h of fermentation period, this being statistically significant only for GSE-O 
at 10h of fermentation. During these first hours, an increase in 
Lactobacillus/Enterococcus group was also found in both cases, although statistical 
significance was only achieved for the fractions with the highest flavan-3-ol monomers 
fraction.52 The chromatographic characterization of grape seed fractions obtained from 
different extraction methods (Aqualsolv and microwave-assisted extraction), reported 
that fractions containing mainly monomers, like catechin and epicatechin, presented low 
antibacterial activity, whereas those fractions containing oligomeric units of catechins 
19 
 
and epicatechins were more effective inhibiting the growth of 10 tested pathogens 
(Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia 
coli, Staphylococcus epidermis, Enterococcus faecalis, Streptococcus pyogenes, 
Haemophilus influenzae, Enterococcus casilliflavus and Pneumococcus).53 When 
comparing the inhibitory capacity of grape seed extracts and grape bagasse extracts in 
relation to the amounts of total phenolics obtained with two different solvent extraction 
methods, GSE had the highest total phenolic concentration resulted from the acetone: 
water: acetic acid extraction.54 In another study, three commercial GSE, which differed 
in their flavan-3-ol profiles, were assayed to test their effect on the growth of several 
Lactobacillus and bifidobacteria strains.55 Briefly, a general inhibition of bacterial 
growth was observed as the most common response. Although dependent on the 
polyphenol extract composition and the bacterial strain tested, this growth repression 
increased with the procyanidin content of the extract and was observed not only to be 
species specific, but also strain specific. Interestingly, even if Lactobacillus and 
Bifidobacteria were likewise sensitive to the phenolic concentration and to the content 
of procyanidins, specific strains such as L. casei and L. plantarum were able to reach 
maximal growth with the three extracts.55 Viveros et al.56 analyzed and compared cecal 
and ileal digesta from broiler chicks treated with GSE and grape pomace concentrate 
(GPC) by plate count and Terminal restriction fragment lenght polymorphism (T-RFLP) 
method. The impact of both extracts on bacterial ecosystem of both regions was noticed 
to differ. Besides, T-RFLP approach made possible to confirm that major changes in 
treated groups were given in uncultured and unidentified species.56 Moreover, the 
combination of grape polyphenols with dietary fiber has been demonstrated to improve 
the desired prebiotic effect. This is the case of grape antioxidant dietary fiber (GADF), a 
natural product derived from red grapes that was demonstrated to boost Lactobacili 
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growth, in rats (50g/kg) but also in vitro, whereby GADF was able to significantly 
increase the growth of L. acidophilus and L. reuteri.57 Extractable polyphenols 
(proanthocyanidins) are an important part of GADF, but there is also an important 
percentage (14.8%) of non-extractable proanthocyanidins (NEPA), which have been 
demonstrated to be metabolized by intestinal microbiota. The confirmed interaction 
between grape derived proanthocyanidins and intestinal bacteria has, in turn, given rise 
to human studies whereby the prebiotic effects of proanthocyanidin-rich extract (0.19 
g/day/subject) intake for 2 weeks, significantly increased the number of Bifidobacterium 
in healthy adults and tended to decrease the number of putrefactive bacteria, such as 
Enterobacteriaceae.58
Berries  
Berries contain abundant phenolic compounds, mostly flavonoids (where anthocyanins 
predominate). Some in vitro studies carried out with diverse berry extracts evaluated 
their antimicrobial activity on Gram-positive and Gram-negative bacteria. Interestingly, 
berry extracts inhibited Gram-negative bacteria, such as intestinal pathogen Salmonella 
enterica, but not Gram-positive beneficial probiotic lactic acid bacteria.59 
Staphylococcus and Salmonella were the most sensitive, and the strongest inhibitory 
action was observed with cloudberry and raspberry, being this outcome largely 
attributed to their ellagitannin content (191 and 146 mg/g, respectively). Importantly, 
the lower pH produced on the media was hypothesized as a possible explanation for the 
antimicrobial action, as it seems that low pH values promote the growth of probiotic 
bacteria, while pathogenic bacteria present high variability in their tolerance to acids.60 
Wild blueberry (Vaccinum augustifolium) is characterized by its high content in 
anthocyanidins, whose prebiotic activity has been documented in vitro and in vivo. 
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Thus, soluble extracts of two New Zealand blueberry cultivars promoted the growth of 
L. rhamnosus and B. breve in vitro and, more importantly, both extracts were 
demonstrated to effectively induce the growth of Lactobacilli and Bifidobacteria in the 
caecum of rats orally gavaged with these extracts (4 mL/kg/day) for 6 days.61 Caecal 
contents of rats treated with supplements, whose major component was the blackcurrant 
extract powder, were also estimated using the Fluorescent in situ hybridization (FISH) 
technology. Rats administered the blackurrant aqueous extract presented a significant 
increase in bifidobacterial numbers and a significant decrease in bacteroides and 
clostridial numbers.62 In an intervention study with 15 healthy male individuals who 
underwent a dietary intervention where a wild blueberry drink was given before or after 
a placebo drink, a significant increase in Bifidobacterium spp. and Lactobacillus 
acidophilus group was also detected.63
Conclusions 
This review has outlined some of the current work carried out facing the impact of 
polyphenols or polyphenol-rich dietary sources on gut microbial ecosystem evidencing 
an interaction between gut microbes and these compounds. When comparing results 
obtained from in vitro studies with data from in vivo experiments, no direct 
extrapolations could be made without a special mention to diverse factors acting up on 
this process. 
Type of in vitro experiments 
In this regard, the in vitro experiments discussed in this work have been performed by 
different approaches, such as in vitro traditional culture techniques or cultivation, in 
vitro faecal batch culture fermentation systems and Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME).  
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Bacteria inoculation with individual polyphenols 
The simplest experiments where diverse bacteria species were inoculated with pure 
polyphenols have been useful to confirm that either flavonoids or non-flavonoids could 
produce an antimicrobial activity against pathogenic bacteria,16 but also a growth 
promoting effect for some beneficial commensal bacteria.26 Nevertheless, the biological 
relevance of these types of outcomes is uncertain, as polyphenols bioavailability is very 
low and they undergo an extensive modification within the organism.64 In this sense, 
special care should be taken as in vitro studies do not consider that some polyphenols 
are directly absorbed in the small intestine, while others reach the colon being degraded 
by microbiota to produce metabolites which, in some cases, could be more active than 
the original compounds.65 There are many review articles that elegantly explain 
polyphenols biotransformation in the gut, which is not the core of this work.15,66 
Anyway, a basic concept such as the fact that the chemical structure of polyphenols 
largely influences their absorption and metabolism should be taken into account. In this 
sense, glycosides that reach the colon will be hydrolysed into aglycones by microflora 
and will subsequently suffer other structural modifications, such as methylation, 
sulfation and glucuronidation processes.64 This is relevant to understand some data from 
in vitro experiments, as for instance the work reported by Duda-Chodak et al.16, who 
concluded that aglycones (naringenin, quercetin and hesperetin) were powerful 
antibacterial compounds compared to their glycosides (naringin and rutin). Therefore, 
when trying to draw any conclusive statement about the biological effect of a certain 
polyphenol, the author´s should be aware of the process of compounds` bioconversion, 
in order to avoid the use of erroneous polyphenols in their experiments.64   
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On the other hand, in these studies a limited number of bacterial species were 
inoculated, ignoring the bacterial complexity found in the intestine. In most cases, a 
limited number of strains from Lactobacillus, Bifidobacterium, Clostridium, 
Staphylococcus, Salmonella, Bacteroides and Escherichia genus16-18,26 were incubated 
with pure polyphenols. Hence, as not all bacterial strains could be evaluated in these 
assays, those microorganisms that have been proved to be responsible for the 
hydrolyzation of some of the tested compounds, as for instance Bacteroides uniformis 
and Bacteroides ovatus, obligate anaerobes that convert rutin to quercetin15 were left 
without being analyzed. Despite these types of experiments are considered the initial 
step for the posterior in vivo experiments, they are essential to gain knowledge for the 
succeeding human subject’s classification on low, medium and high polyphenol 
metabolisers. This is the case of daidzein, a soy isoflavone, whose metabolism gives 
equol (whose biological properties might be beyond its precursors`) when equol-
forming bacteria are present in the intestine.67 Knowledge about the conversion of the 
mentioned compound has allowed discerning a great variability between individuals 
regarding their ability to produce its metabolite, attributed to differences in their gut 
microbiota composition.68 This sort of information might be useful for personalized 
nutritional recommendations in the future. Anyway, there are other factors apart from 
the hosts` baseline gut microbiota composition, such as genetics and the metabolic state 
of the host that should be considered in order to be able to clarify the exact mechanisms 
contributing to the health benefits and to distinguish the direct correlation between 
bacterial strains and the metabolic products resulted from their interaction with 
polyphenols. 
Batch culture fermentation system 
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In this regard, the use of batch culture fermentation systems has been also reported in 
this work.27 This approach, characterized to exhibit similar conditions to the human 
colonic region, aims to assess the effect of polyphenols27 or polyphenol-rich extracts 
27, , ,30 39 61 on the growth of faecal bacteria population using human faecal slurries. Even if 
these systems are static models that aim to give information about colonic degradation 
of polyphenols and allow scientists to fix strict conditions regarding oxygen, 
temperature and pH of the medium, an important point to bear in mind is that faecal 
samples used might not entail the same characteristics of daily faecal production. 
Moreover, one of the main limitations when trying to address the gut microbial 
polyphenol metabolism in these types of assays is the interindividual variability. Faecal 
samples obtained from different individuals will exhibit distinct bacterial population for 
numerous reasons (i.e. diet, exercise, water, absorption/hydratation state, minor 
infections, stress and so on), thus they could present a variable metabolic capacity69 
giving rise to different conclusions.  
Simulator of the Human Intestinal Microbial Ecosystem (SHIME) 
Another undeniable factor affecting results is the repercussion of the experiments´ 
duration. In contrast to the aforementioned in vitro static systems, continuous multi- 
staged culture systems that simulate the human microbial community in the large 
intestine have been developed.70 Studies carried out in SHIME models32,43 have allowed 
scientists to assess in vitro the implication of a two-week continuous treatment period 
with black tea, wine extract or a soygerm powder in colonic microbiota composition. As 
a matter of fact, even if this system is considered to better mimic the real polyphenol-
gut microbial interaction happening in the organism, it should be underlined that this 
approach takes for granted that the extracts reach intact to the colonic region, which is 
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far from the reality.15 Moreover, owing to the high inter-relationship between host 
factors and the complex intestinal bacteria community, in vitro studies should be 
supported with further research in vivo and with human intervention trials to be able to 
elucidate the mechanisms underlying this interaction. 
In vivo studies and human intervention studies 
This review summarizes data from 16 studies conducted in animal models compared to 
8 human intervention studies. It is widely known that preliminary evidences should be 
warranted in animal models before human intervention trials. In fact, they contribute to 
better understand the mechanisms and biological effects that could be likely to happen 
in human biology. Furthermore, a good design in human studies is indispensable in 
order to make as feasible as possible the conclusions drawn. In many cases it can be 
difficult to count on volunteers collaboration who meet the criteria and are ready to 
begin a relatively long-term study (4 to 10 weeks), so that the number of participants 
enrolled might be quite poor (8 subjects to 22 subjects). This might lead the researchers 
to sketch crossover studies30 in which participants are randomly subjected to a sequence 
of two or more treatments, and allow removing participants’ variation, as well as being 
more efficient than trials performed in parallel with the same number of subjects. 
However, their principal disadvantage is that the effects of one treatment might 
“carryover” and modify the response to the following treatments. In fact, some trials 
cited in the present work40 have skipped the wash out periods between treatments that 
might be key in order to favour the continuation of the study by the participants.  
Quantification techniques  
The final technique used for the bacteria identification and quantification is of great 
relevance. It is widely known that 60-80% of bacterial species have been reported to be 
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non-cultivable by culture-dependent methods. Thus, these approaches failed to identify 
a large fraction of gut microbial diversity. Interestingly, at present, the advances gained 
in molecular techniques have made possible to overcome limitations of culture 
dependent methods71 being able to give a more representative view of all bacterial 
community in the gut. Nevertheless, these techniques should be complementary, and 
ideally an inter-disciplinary approach comprising several “omics” approaches without 
the exclusion of culture-dependent techniques should be conducted. An example of this 
combination could be found in an experiment performed by Kemperman et al.32, where 
data obtained from different microbiological analyses (cultivation, qPCR, PCR-DGGE 
and 16S rRNA pyrosequencing) were compared and the previously mentioned 
limitations of traditional culture techniques became visible. The culture-dependent 
technique used in this experiment estimated a lower bacterial number and was not able 
to detect conclusive antimicrobial effect of the extracts tested, whereas the 
aforementioned techniques were able to distinguish different bacterial clusters 
depending on the tested compounds.32 In general, from the articles cited in this review, 
it could be suggested that culture-dependent techniques were mainly focused on the 
identification/quantification of six genus (Lactobacillus, Bifidobacterium, Escherichia, 
Salmonella, Staphylococcus and Bacillus) belonging to one of three major classes 
(Firmicutes, Proteobacteria, Actinobacteria),31, , ,33-35 57 61 while those studies performed 
with accurate and powerful molecular techniques, such as 16S rRNA pyrosequencing, 
FISH, FISH-FCM and PCR-DGGE, enabled the characterization of genus (Victivallis, 
Akkermansia) from not so abundant phyla (Chlyamydiae/Verrucomicrobia group) and 
conduct an in-depth characterization of bacterial populations at species levels. However, 
briefly, it could be said that even a lot of progress has been made in the last years in the 
area of gut microbiota, still some challenges regarding parameters such as sampling, the 
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sequencing depth and setting the limits of the regions to be analyzed remain to be 
agreed so that experiments could be completely reproducible. The advances in 
sequencing technology will permit to detect all the bacterial species and strains, at a 
level of detail much more precise than the previously used techniques. 
Final remarks 
From a health perspective, the intake of phenolic compounds, either as pure compounds 
or as part of food constituents, could be an effective approach to modulate gut 
microbiota, enhancing the growth of specific beneficial bacteria strains, while 
competitively excluding specific pathogenic bacteria. However, further research is 
needed, especially in humans, to elucidate the specific effects of phenolic compounds 
on the growth of different gut bacteria, their interactions with other polyphenols and 
dietary components, the individual genetic, inflammatory and microbiota background, 
as well as the involvement of polyphenol-microbiota interactions on the beneficial 
effects attributed to polyphenols on different chronic diseases. 
ABBREVIATIONS USED 
NO, nitric oxide; MIC, minimum inhibitory concentration; Clostridium coccoides- 
Eubacterium rectale, Erec; IC50, half maximal inhibitory concentration; BMI, body mass 
index; LCF, low-cocoa flavanol; HCF, high-cocoa flavanol; CRP, c-reactive protein; 
GTE, green tea extract; GT, green tea powder; Lp, Lactobacillus plantarum DSM 
15313; RW, red wine; DRW, de-alcoholized red wine; SHIME, Simulator of the Human 
Intestinal Microbial Ecosystem; PPE, pomegranate peel extract; GSE, grape seed 
extract; GSE-M, monomeric-rich fraction of grape seed extract; GSE-O, oligomeric-rich 
fraction of grape seed extract; GPC, grape pomace concentrate; T-RFLP, Terminal 
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Restriction Fragment Length Polymorphism; GADF, grape antioxidant dietary fiber; 
NEPA, non-extractable proanthocyanidins; FISH, Fluorescent in situ hybridization. 
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Table 1. Polyphenolic-rich Beverages (Cocoa, Tea, Wine) With Potential Effects On Gut Microbiota Composition 
Food or food 
extracts rich in 
polyphenols 
Type of 






promoting effect (BGPE) Reference 
a  Cocoa Animal study 6 weeks 10% (w/w) FISH-FCM ‐ Bacteroides genus 
29‐ Clostridium genus  (10.62 mg/g polyphenols) 
‐ Staphylococcus genus 
       
Cocoa drink Human 
intervention 
4 weeks HCFb FISH ‐ Clostridium histolyticum group ‐ Eubacterium rectale-  
C. coccoides group  (494 mg cocoa flavanols) 
‐ Lactobacillus spp. 
‐ Enterococcus spp 
‐ Bifidobacterium spp. 
       
c   LCF     ‐ Eubacterium rectale-  
C. coccoides group (29 mg cocoa flavanols) 30
‐ Clostridium histolyticum group  
‐ Lactobacillus spp. 
‐ Enterococcus spp. 
       








‐ Clostridium histolyticum group ‐ Lactobacillus spp. 
‐ Bifidobacterium spp. 
(1 mg/mL; 0.4 mg/mL 
flavanols) 
        
Black tea 
extract 
In vitro study 2 weeks 1000 mg/day SHIMEd and 
qPCR
‐ Klebsiella sp. ‐ Bifidobacteria 
‐ Blautia coccoides e ‐ Enterococci / 
Pyrosequenc
ing 
32‐ Anaeroglobus ‐ Akkermansia 
 ‐ Victivallis 





4 weeks Suphenon®   Plate count ‐ Clostridium spp. ‐ Bifidobacterium spp 35‐ Clostridium perfringens  (0.4 g/3 times per day)  
        
        
        




Table 1. Continued 
Food or food 








Bacteria growth promoting 
effect (BGPE) Duration Dosis Reference 
In vitro study Green tea 
extract           
2 days 10 mg extract/disc Plate count  ‐ Clostridium difficile ATCC 
9689 incubation   
 ‐ Clostridium perfringens ATCC 
13124 
‐ Clostridium perfringens B-3-7 
‐ Clostridum perfringens B-3-8 
‐ Clostridium perfringens B-165-
16 31
‐ Clostridium perfringens C-01 
‐ Clostridium paraputrificum B-
3-4 
‐ Clostridium paraputrificum B-
78 
‐ Clostridium paraputrificum 
VPI-6372 
        
Tea 
polyphenols 
Animal study 2 weeks 0.2% tea polyphenols Plate count ‐ Bacteroidaceae ‐ Lactobacilli 33 





11 and 22 
weeks  
4% w/w of GTf + qPCR and   ‐ Lactobacillus 
Lactobacillus plantarum T-RFLPg 37
DSM 15313 
 
        
Green tea  Human 
intervention 
10 days 1000 mL/day qPCR and  ‐ Bifidobacterium spp. 
  T-RFLP 36
 
        
        
        
        
        




Table 1. Continued 
Food or food 









promoting effect (BGPE) Duration Dosis Reference 
Green Tea 
extracts 
In vitro study 2- 3 days 
incubation 
GTE-1h  Agar plate 
dilution 
method 
 ‐ Staphylococcus aureus I-001 
(125 µg/mL) (> 60% polyphenols) 
‐ Staphylococcus epidermis 
KK108  
(125 µg/mL) 
‐ Streptococcus spp. K003 (200 
µg/mL) 
‐ Corynebacterium suis 54001 
(750 µg/mL) 
‐ Escherichia coli KK88 MN1 
(400 µg/mL) 
‐ Escherichia coli KK88 G1253 
(400 µg/mL) 
‐ Salmonella spp. O4 type K-011 
(200 µg/mL) 
       
   GTE-2   ‐ Staphylococcus aureus KK101 
(50 µg/mL) 34 (> 80% polyphenols) 
‐ Staphylococcus epidermis 
KK108 (50 µg/mL) 
 
‐ Streptococcus uberis KK204 
(200 µg/mL) 
‐ Salmonella dublin L-729 (200 
µg/mL) 
‐ Salmonella enteriditis L-58 
(200 µg/mL) 
‐ Salmonella infantis L-164 (200 
µg/mL) 
‐ Salmonella mbandaka L-743 
(200 µg/mL) 
‐ Salmonella sofia L-59 (200 
µg/mL) 
‐ Salmonella typhimurium L-413 
(200 µg/mL) 
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Table 1. Continued 
Food or food 









promoting effect (BGPE) Duration Dosis Reference 
 Animal study 4 weeks GTE-1  Counting on 
culture 
medium 
‐ Clostridium perfringens ‐ Bifidobacterium spp. 
 ‐ Lactobacillus spp. (> 60% polyphenols) 34GTE-2  
(> 80% polyphenols) 
        
In vitro study Wine phenolic 
extract 















4 weeks PCR- 
DGGE
‐ Bacteroidetes ‐ Fusobacteria De-alcoholized red wine i ‐ Firmicutes ‐ Enterococcus genus  (272 mL/day)   ‐ Blautia coccoides- 
Eubacterium rectale 
‐ Bifidobacterium 
‐ Eggerthella lenta 
      
   Red wine (272 mL/day)   ‐ Proteobacteria 
‐ Prevotella  
40‐ Bifidobacterium 




‐ Enterococcus genus 
‐ Blautia coccoides- 
Eubacterium rectale 
‐ Bacteroides genus 
‐ Bacteroides uniformis sp. 
        




Table 1. Continued 
Food or food 









promoting effect (BGPE) Duration Dosis Reference 
In vitro study Red wine 
grape extract 




‐ Klebsiella sp. ‐ Bifidobacteria 
‐ Blautia coccoides ‐ Alistipes 
32‐ Anaeroglobus ‐ Cloacibacillus 
‐ Subdoligranulum ‐ Victivallis 
‐ Bacteroides ‐ Akkermansia 
        
aFISH-FCM, Fluorescence in situ hybridization coupled to flow citometry; bHCF, high- cocoa flavanol; cLCF, low- cocoa flavanol; dSHIME, Simulator of the Human 
Intestinal Microbiota Ecosystem; eqPCR, quantitative Polymerase Chain Reaction; fGT, green tea powder; gT-RFLP, Terminal restriction fragment length polymorphism; 
hGTE, green tea extract; iDGGE, Denaturing gradient gel electrophoresis; j bw; body weight. 
Wine 
polyphenols 





‐ Clostridium spp. ‐ Bifidobacterium spp. 
‐ Bacteroides 













(AMA)  Type of study Duration Dosis Reference 
Soygerm powder In vitro study 14 days 2.5 g/day SHIMEa and 
plate count 
 ‐ Lactobacillus spp. 
43
       
Aqueous soy extract Animal study 60 days HUFb Plate count after 
faecal 
inoculation 
‐ Enterococcus spp. ‐ Enterobacteria 
  (2.8 mL/kg bwc ‐ Clostridium spp. /day) 
      
   HFd  ‐ Bifidobacterium 
spp. 
‐ Enterobacteria 
 (2.8 mL/kg bw/day) 
‐ Lactobacillus spp. 45
‐ Enterococcus spp. 
      
    ‐ Bifidobacterium 
spp. 
‐ Enterobacteria 
HIFe ‐ Clostridium spp.  (2.8 mL/kg bw-2.1 mg of 
‐ Lactobacillus spp.  total isoflavone/kg bw/day) 
‐ Enterococcus spp.  
       




 ‐ Enterococci 
‐ Lactobacillus spp. (3 mL/kg bw/day)  ‐ Bacteroides spp. 
44
      
    ‐ Clostridium spp. ‐ Lactobacillus spp. Unfermented soy product      
‐ Bifidobacterium spp. (3 mL/kg bw/day)  
       
       
       
       
       
       
40 
 









(AMA)  Type of study Duration Dosis Reference 
Soy- milk Human 
intervention 
3 moths Low glycinin soymilk qPCRf and FLX 
pyrosequencing 
‐ Bifidobacterium ‐ Bacteroides- 
Prevotella ‐ Firmicutes 500 mL/day 
 ‐ Bacteroidetes 
‐ Proteobacteria 41
      
   Conventional soymilk  ‐ Bifidobacterium ‐ Bacteroidetes 
‐ Firmicutes ‐ Proteobacteria 500 mL/day 







Exclusive feeding PCR- DGGEg  ‐ Bifidobacterium 
infantis   
‐ Bifidobacterium  




        
Pomegranate  
by-product 





1.5 mL of PPEh Batch culture 
fermentationmo
del / FISH





       
Pomegranate extract Animal study 25 days 250 mg/kg Agar plate 
dilution method 
‐ Escherichia coli ‐ Lactobacilli 
46‐ Bifidobacteria ‐ Enterobacteria 
‐ Clostridium 
       
Pomegranate peel extract Animal study 4 week 0.2% (6 mg/day) qPCR  ‐ Bacteroides- Prevotella 
spp. 47  
‐ Bifidobacterium spp. 
       
       














(AMA)  Reference Type of study Duration Dosis 
In vitro study Pomegranate by-product 
 
0-72 h 0.01% (v/v) of PPE Counting on 
culture medium 






 ‐ Clostridium ramosum 
NRRL B-23617 ‐ Bifidobacterium 
breve NRRL B-
41408 
‐ Staphylococcus aureus 
ATCC 29213 
‐ Lactobacillus acidophilus 
NRRL B-4495 26
‐ Lactobacillus pentosus 
NRRL B-227 
‐ Lactobacillus rhamnosus 
NRRL B-442 
‐ Bifidobacterium bifidum 
NRRL B-41410 
 
        




(414 mg/g total phenolics) 
Culture medium 
Spectrophotome
try (600 nm) 








 at 0.25-1 mg/mL 
 






 55‐ Lactobacillus acidophilus 
LA-5 GSE-O
k 
‐ Lactobacillus casei 
IFPL7190 (279 mg/g total phenolics) 
at 0.25-1 mg/mL 
‐ Lactobacillus vaginalis 
ZL63-22 ‐ Lactobacillus 
bulgaricus LBY-
27 
‐ Bifidobacterium lactis 
BB12 
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(AMA)  Type of study Duration Dosis Reference 
In vitro study Grape seed extract 18-24 h 
incubation 
 
Acetone: water: acetic acid Paper disc 
diffusion 
method 
 ‐ Aeromonas hydrophila 
ATCC 7965 (90:9.5:0.5), 667.87 mg 
 GAEl/g ‐ Bacillus brevis FMC 3 
At 20% ‐  Bacillus cereus FMC 19 
 ‐  Bacillus megaterium 
DSM 32 Ethyl acetate:methanol: 
water (60:30:10), 627.98 
mg GAE/g 
‐ Bacillus subtilis IMG 22 
‐ Enterobacter aerogenes 
CCM2531 At 20% 
‐ Enterococcus faecalis 
ATCC 15753 
‐ Escherichia coli DM 54
‐ Klebsiella pneumoniae 
FMC 5 




‐ Proteus vulgaris FMC 1 
‐ Pseudomonas  
aeruginosa ATCC 
27853 
‐ Staphylococcus aureus 
COWAN 1 
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grape seed extract 
 
 
0.5 g/day/subject extract 









        




22-26 h Non-Extractable 
polyphenols 








       57
 Animal study 4 weeks 50 g/kg diet RT- PCR ‐ Bifidobacterium spp. ‐ Lactobacillus spp. 




        
In vitro study Grape pomace cocentrate 24 h 
incubation 
GSE (7.2 g/kg) Paper disc 
diffusion 
method 
 ‐ Clostridium perfringens  
BA05/00439- 5B and grape seed extract   
 
 




 ‐ Desulfitobacterium 
hafniense  56       
   GSE (7.2 g/kg)   ‐ Pseudomonas/Acino
bacter spp. 
















(AMA)  Type of study Duration Dosis Reference 
 Wild blueberry Human 
intervention 
6 weeks 25g/day RT- PCR ‐ Lactobacillus 
acidophilus  63‐ Bifidobacterium 
spp. 
        
Blackurrant extract 
powder 
Animal study 4 weeks Blackcurrant extract 
powder 




‐ Lactobacilli  





   Blackcurrant extract 
powder, lactoferrin and 
lutein 
 ‐ Bacteroides ‐ Bifidobacteria 
 ‐ Clostridium perfringens/ 
histolyticum sub. grp. 
30 mg/kg bw/day 
 
       
In vitro study Berry extracts 12-24 h 
incubation 
 
1-5 mg/mL Counting on 
culture medium 
 ‐ Staphylococcus aureus E-
70045 
Cloudberry ‐ Salmonella enterica sv. 
Typhimurium E-981151 60Raspberry  ‐ Salmonella enterica sv. 
Infantis E-97738 
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(AMA)  Reference Type of study Duration Dosis 
In vitro study Berry extracts 12-24 h 
incubation 
0.8-3.5 mg/well Agar diffusion 
method 
 ‐ Escherichia coli 50 
‐ Escherichia coli CM871  




‐ Lactobacillus rhamnosus E-
800  
‐ Salmonella enterica SH-
5014 
      
   Raspberry   ‐  Lactobacillus rhamnosus 
E-666 
‐ Lactobacillus rhamnosus E-
800 
‐ Lactobacillus reuteri E-849 
‐ Escherichia coli 50 
‐ Escherichia coli CM871 
59‐ Salmonella enterica SH-
5014 
      
   Cloudberry   ‐ Lactobacillus rhamnosus E-
666 
‐ Escherichia coli 50 
‐ Escherichia coli CM871 
‐ Salmonella enterica SH-
5014 
‐ Enterococcus faecalis E-
203 
‐ Bifidobacterium lactis E-
508 
      
   Strawberry   ‐ Escherichia coli CM871 
‐ Bifidobacterium lactis E-
508 
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(AMA)  Type of study Duration Dosis Reference 
   Lignon-berry   ‐ Escherichia coli 50 
‐ Escherichia coli CM871 
‐ Salmonella enterica SH-
5014 
      
   Blackurrant   ‐ Escherichia coli 50 
‐ Escherichia coli CM871 59      
   Cranberry   ‐ Escherichia coli 50 
‐ Escherichia coli CM871 
‐ Salmonella enterica SH-
5014 
      
   Sea buckthorn berry   ‐ Escherichia coli CM871 
       
In vitro study Blueberry extract 1-5 days 
incubation 
Maru cultivar blueberry 
extract 
Plate count  ‐ Bifidobacterium 
breve 
NZRM3932 10-25% (v/v) 
       
   Centurion cultivar 
blueberry extract  
  ‐ Lactobacillus 
rhamnosus 
NZRM 299 10-25% (v/v) 61‐ Bifidobacterium 
breve 
NZRM3932 
  48 h 
incubation 




 ‐ Lactobacilli 
‐ Bifidobacteria 
      
             








aSHIME, Simulator of the Human Intestinal Microbiota Ecosystem; bHUF, hypecholesterolem fermented soy product; ic plus un cbw: body weight; dHF, fermented soy 
product; eHIF, hypercholesterolemic plus isoflavone- supplemented fermented soy product; fqPCR, Polymerase Chain Reaction; gDGGE, Denaturing gradient gel 
electrophoresis; hPPE, pomegranate by-product; iFISH, Fluorescence in situ hybridization; jGSE-M, monomeric- rich fraction grape seed extract; kGSE-O, oligomeric-rich 
fraction grape seed extract; lGAE, gallic acid equivalent; mGPC, 7grape pomace concentrate; nT- RFLP, Terminal restriction fragment length polymorphism with specific 




Table 2. Continued 
Food or food extracts rich 









 Animal study 6 days 4 mL/kg bw/day from Maru 
cultivar 
FISH  ‐ Lactobacilli 
‐ Bifidobacteria 
      
   4 mL/kg bw/day from 
Centurion cultivar 
  ‐ Lactobacilli 
‐ Bifidobacteria 
61
      
Apples and apple products Animal study 14 weeks 
 





‐ Bacteroides   
48
      
Apple juice Animal study 4 weeks 
 
Free access  
 
Plate count  ‐ Bifidobacterium 
‐ Lactobacillus 49
      
Apple juice colloid Animal study 6 weeks 
 






‐ Bacteroidaceae  
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